Literature DB >> 890699

A hypothesis concerning possible new derivatives of daunorubicin and adriamycin with enhanced DNA-binding properties.

S Neidle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 890699

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy.

Authors:  M Manfait; A J Alix; P Jeannesson; J C Jardillier; T Theophanides
Journal:  Nucleic Acids Res       Date:  1982-06-25       Impact factor: 16.971

3.  Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.

Authors:  Masashi Shin; Hayato Matsunaga; Kunio Fujiwara
Journal:  Histochem Cell Biol       Date:  2010-04-28       Impact factor: 4.304

4.  Intravesical idarubicin--a phase-I study.

Authors:  W Schultze-Seemann; K Mross; K Burk; H Sommerkamp
Journal:  Urol Res       Date:  1994

Review 5.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.